Clavis Pharma ASA : Clavis Pharma ASA : Call for Extraordinary General Meeting
Oslo, Norway, 11 April 2013
Clavis Pharma ASA (OSE: CLAVIS), announces that the Board of Directors
convenes the shareholders of Clavis Pharma ASA to an extraordinary general
meeting to be held on 2 May 2013 at 13:00 at Parkveien 53 B, Oslo.
The general meeting will be opened by Anders P. Wiklund, the Chairman of the
The Board of Directors has been contacted by one of the Company's
shareholders, Tycoon Industrier AS, holding 7.4 % of the issued shares in the
Company. Tycoon Industrier AS has with reference to the public limited
liability companies' act section 5-7(2) required that the Board of Directors
calls an extraordinary general meeting to handle item 4 below. The election
committee is considering the proposals to be made, and the election
committee's recommendation will, when finalized, be available at the company's
The following agenda has been set for the general meeting:
1.Opening of the meeting and registration of attending shareholders (no
2.Election of the chairman of the meeting and a person to co-sign the
3.Approval of the notice of the meeting and the agenda
4.Election of board of directors
Enclosed to this notice of attendance are the attendance slip and proxy form.
Shareholders who wish to attend the general meeting are asked to return a
signed version of the enclosed attendance slip within 29 April 2013, 17:00 CET
to Nordea Bank Norge ASA, Issuer Services, P.O. Box 1166 Sentrum, 0107 Oslo,
Norway, or fax +47 22 48 63 49. Notice may also be given via
ww.clavispharma.com. Shareholders that cannot be present are requested to
return a signed version of the enclosed proxy form to the same mailing address
within 29 April 2013, 17:00 CET.
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Moteseddel og fullmakt 2013
Attendance slip and proxy 2013
Call for EGM - April 2013
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Clavis Pharma ASA via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.